HEALTH: Sept. 2021) — Record numbers of COVID -19 cases have been reported in children. Pfizer and BioNTech announced that their mRNA vaccine to combat COVID -19 was safe and seems to produce a protective immune response in children as young at 5.
The companies have been testing a lower dose — just 10 mg — with children aged 5 and 11.. This is one-third of the adult dose.
In a clinical study that involved more than two ,200 kids, Pfizer found that three weeks apart, two doses of vaccines produced a high level neutralizing antibodies. This was comparable to what is seen in older children who receive a higher dose.
The FDA asked vaccine manufacturers to include more children into these studies, following the advice of its vaccine advisory panel.
Instead of testing whether vaccines prevent COVID -19 illness among children as it did with adults, the FDA asked vaccine manufacturers to include more children in these studies. In an effort to speed up vaccines for children, the FDA approved this approach. Children are now back at school in all parts of the U.S With that in mind Evan Anderson, MD, a pediatrician with Children’s Healthcare of Atlanta, said that it’s important to remember that no efficacy data was shared by the company today.
We don’t know if there were any cases of COVID in children who were enrolled in this study or how they compare to those who were given vaccine.
The company claims that side effects observed in the trial were similar to those in older children. According to the company, there was no evidence of myocarditis (heart inflammation) in any of the cases. Pfizer states that they will send the FDA their data as soon as possible.
The company claims that side effects observed in the trial were similar to those in older children. Pfizer states that they will send the FDA their data as soon as possible.
Section F Family Children News – dWeb.News
More dWeb.News Family and Children News https://dweb.news/category/dweb-news/section-f-family-children-kids-news/